GlassScriptPhysician profile
Muhammad U Dogar
NPI 1619226677
$4,471.68
in general payments reported to CMS, 2019-2025
27 companies · $568 in 2025
The $568 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $733 · 2021: $279 · 2022: $822 · 2023: $536 · 2024: $1,097 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,199.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,003.29 | 2019-2023 | Pressurewire |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $470.05 | 2019-2021 | |
| Astellas Pharma US INC | $381.96 | 2020-2023 | Xtandi |
| Medtronic, INC. | $363.72 | 2024 | Onyx Frontier, Linq II |
| Novartis Pharmaceuticals Corporation | $258.94 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $212.27 | 2019-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $202.49 | 2019-2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $165.97 | 2023-2024 | Avvigo Guidance System, Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.72 | 2023-2024 | Jardiance |
| Abiomed | $149.91 | 2024-2025 | Impella |
| Philips North America LLC | $137.28 | 2022-2025 | Angiosculpt Cv Rx |
| Pfizer INC. | $126.26 | 2021-2025 | |
| Lexicon Pharmaceuticals, INC. | $125.00 | 2024 | Inpefa |
| Janssen Pharmaceuticals, INC | $107.41 | 2022-2024 | Xarelto |
| Scpharmaceuticals INC. | $93.77 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $83.34 | 2022 | |
| Merck Sharp & Dohme LLC | $83.32 | 2023 | Verquvo |
| Inari Medical, INC. | $75.89 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Novo Nordisk INC | $51.60 | 2025 | Wegovy, Rybelsus, Ozempic |
| Alnylam Pharmaceuticals INC. | $51.52 | 2025 | Onpattro |
| Kestra Medical Technology Services, INC. | $33.81 | 2022 | |
| Cordis US Corp. | $31.24 | 2023-2025 | Rain Sheath, Rain Sheath Transradial |
| Amgen INC. | $31.03 | 2025 | Repatha |
| Cardinal Health 200 LLC | $18.71 | 2021 | |
| Lilly USA, LLC | $17.28 | 2025 | Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $17.06 | 2024 | |
| Terumo Medical Corporation | $13.84 | 2025 | Metacross Otw |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Dogar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.